Clinical features of Pompe disease

Area of Science:

• Biochemistry
• Genetics
• Metabolic Disorders

Background:

• Glycogen storage disease type II, or Pompe disease, is an autosomal recessive metabolic disorder.
• It stems from a deficiency in the lysosomal acid alpha-glucosidase enzyme, leading to glycogen accumulation within lysosomes.
• Pompe disease is genetically linked to mutations in the acid alpha-glucosidase (GAA) gene on chromosome 17q25.2-q25.3.

Purpose of the Study:

• To describe the genetic basis and clinical spectrum of Pompe disease.
• To correlate residual GAA enzyme activity with disease phenotypes.
• To elucidate the inheritance pattern and molecular underpinnings of Glycogen storage disease type II.

Main Methods:

• Genetic analysis of the GAA gene.
• Enzyme activity assays for acid alpha-glucosidase.
• Clinical phenotyping and patient stratification based on disease onset and severity.

Main Results:

• Pompe disease is confirmed as an autosomal recessive disorder caused by GAA gene mutations.
• A direct relationship exists between residual GAA activity levels in muscles and the observed clinical phenotypes.
• The study outlines a spectrum of phenotypes, from severe classical early-onset to milder non-classical late-onset forms.

Conclusions:

• Pompe disease is characterized by variable clinical presentations directly influenced by residual acid alpha-glucosidase enzyme activity.
• Understanding the genotype-phenotype correlation is crucial for diagnosing and managing Pompe disease.
• The genetic and enzymatic basis of Glycogen storage disease type II dictates its diverse clinical manifestations.